Avanos Medical Appoints Sig Delgado as Senior VP

Avanos Medical, Inc. has appointed Sigfrido (Sig) Delgado as the senior vice president of integrated supply chain. Delgado joins the company with over 20 years of experience in manufacturing, supply chain, and operations within the medical device industry, having most recently served as the vice president of the global medical technology business at Jabil Healthcare.

Avanos' CEO, Joe Woody, emphasized the importance of executing a robust sales, inventory, and operations planning strategy, stating that Delgado's deep experience within the medical device industry will be critical in achieving the company's goals and building upon the strong foundation established in this area.

Delgado holds a bachelor's degree in mechanical engineering from the Massachusetts Institute of Technology and a master's degree in engineering management from Florida International University. He is also a certified six sigma black belt and is fluent in Spanish.

Avanos Medical, Inc. is a medical technology company committed to delivering clinically superior medical device solutions to address important healthcare needs, including providing nutrition to patients from hospital to home and reducing the use of opioids while aiding patients in their transition from surgery to recovery. The company develops, manufactures, and globally markets its recognized brands, holding leading market positions in multiple product categories. As a result of these announcements, the company's shares have moved 1.5% on the market, and are now trading at a price of $19.88. For the full picture, make sure to review Avanos Medical's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.